X-linked sideroblastic anemia (XLSA) is caused by mutations in the erythroid-specific 5-aminolevulinate synthase gene (ALAS2). XLSA was diagnosed in a 32 year old female with a mild phenotype and moderately late onset. Pyridoxine therapy had no effect in the proband, but in her affected son engendered a modest increase in hemoglobin concentration and a four-fold reduction in ferritin iron. Molecular analysis identified a C to G transversion at nucleotide (-)206 from the transcription start site, as defined by primer extension, in the proximal promoter region of ALAS2. No other mutations were found in the promoter region, the flanking intronic sequences, the exons, or the 3' genomic region. The same mutation was found in her affected son but not in any other of her unaffected relatives. The mutation resulted in a 94% loss of activity relative to the wild-type sequence for a luciferase reporter construct containing the proximal 293 nt of the ALAS2 promoter when transfected into human erythroid K562 cells. Confirming the mutation's deleterious effect, ALAS2 mRNA level in the proband's erythroid precursors was reduced 87%. The mutation occurred in or near three different putative transcription factor binding sites of unknown erythroid importance. The dramatic decreases in reporter activity and mRNA level suggest that the region of the mutation may bind a novel and important erythroid regulatory element.
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For personal use only. on . by guest www.bloodjournal.org From INTRODUCTION X-linked sideroblastic anemia (XLSA; OMIM 301300) a is caused by the deficient activity of the erythroid-specific form of the mitochondrial enzyme, 5-aminolevulinate synthase [E.C.
2.3.1.37; ALAS2]. [1] [2] [3] Over 25 different mutations in the erythroid ALAS2 gene have been identified in XLSA patients. 4, 5 All of these mutations have been single base substitutions within the region of the enzyme conserved in prokaryotes (encoded by exons 5-11), leading to either an altered amino acid and reduced ALAS2 activity and/or stability or in one case, to an early stop codon resulting in a truncated protein with little or no enzymatic activity. 4, 6 The clinical phenotype for XLSA is microcytic, hypochromic anemia with iron accumulation.
Severity varies widely depending on the amount of residual enzymatic activity with onset of anemia typically during youth but ranging from birth 2, 7 to the ninth decade of life. 8, 9 While probands are frequently males, due to hemizygosity of the X-linked defect, females are occasionally affected, most likely due to skewed X-chromosome inactivation in favor of sparing the mutant allele. 8 The enzymatic reaction catalyzed by ALAS2 requires pyridoxal 5'-phosphate as a cofactor, and most published ALAS2 mutations have resulted in pyridoxine-responsive phenotypes as measured by consistent, even if slight, increases in hemoglobin concentration following vitamin supplementation. 4, 6 This is particularly apparent if iron overload has been ameliorated by phlebotomy or chelation therapy. In this report, we describe a female proband with XLSA who had a mutation in the proximal promoter region of the ALAS2 gene. Her affected son also had this mutation and was mildly pyridoxine-responsive. This mutation is the first promoter mutation identified in XLSA patients and occurred in a potential transcription factor binding site, dramatically reducing the activity of a luciferase reporter construct in erythroid K562 cells and the level of ALAS2 mRNA in the proband's erythroid precursors.
CASE REPORTS AND METHODS
Case report Family 10 (Families 1 to 9 were identified in this laboratory as previously described. 5 ). The proband of Family 10 (II-4; Fig 1) was a female of Welsh descent (d.o.b. 16 May, 1944 ) who presented at the University Hospital of Wales at age 32 with a long-standing history of tiredness that had worsened over the previous year, breathlessness with physical exertion such as climbing stairs, and excessive perspiration.
The blood film showed anisocytosis, hypochromia and microcytosis. Laboratory analyses revealed hypochromic anemia with a hemoglobin (Hb) concentration of 10.6 g/dL (nl = 11.5 to 15.5) and MCH of 26.0 pg (nl = 27 to 34). There was slight microcytosis (MCV 80 fl; nl = 80 to 99). The size distribution of the red cells (Coulter Z-B1 counter and the C2000 Channelyzer, Beckman Coulter, Fullerton, CA) was broad, with a shift towards microcytic cells. The hemoglobin concentration distribution was also broad and strongly shifted towards hypochromic cells. Hemoglobin electrophoresis profile and globin chain synthesis ratio were normal. Her platelet count was low and her white cell count was at the lower limit of normal. Her hematologic picture was essentially unchanged from records at age 26 (Hb 10.1 g/dL, MCH 25.9
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Analysis of iron at presentation (age 32 yr) showed increased stores (serum ferritin 982 µg/L, nl = 15 to 200; serum iron 46 µmol/L, nl=5 to 25; TIBC 60 µmol/L, nl = 49 to 78; transferrin saturation 78%, nl mean = 30%), possibly related to the prior iron supplementation.
The bone marrow was hypererythroid with dyserythropoiesis and 70% ringed sideroblasts.
Myelopoiesis and thrombopoiesis were normal. Ferrokinetics showed increased marrow iron turnover (MIT; 369 µmol/L blood/d; nl = 70 to 140) with 84% ineffective erythropoiesis (nl = 20 to 30%) and a red cell lifespan of 95 days (nl = 65 to 145) 10 . A putative diagnosis of hereditary sideroblastic anemia was made (based on her relatively young age, her persistently low MCH and her borderline normal/low MCV) and was confirmed by the presence of ringed sideroblasts in her son at age 8. She was placed on a regimen of folic acid and 150 to 300 mg/d pyridoxine with no change in hemoglobin concentration. Perhaps the response was attenuated due to inhibition by her excess iron. In previous studies, it has been noted that pyridoxine responsiveness can be recovered after removing excess iron stores. The proband's mother had been anemic (possibly aggravated by a gastric ulcer) and took iron supplements. Her red cell size distribution was broad also -somewhat similar to, but not as flanking sequence and 350 bp of 3' flanking sequence were accomplished as previously described. 2, 5 For confirmation of the promoter mutation by restriction analysis, mismatch PCR was designed using primers listed in Table 1 and the Expand High Fidelity System (Roche Molecular Biochemicals, Indianapolis, IN). The mismatch in the sense primer (#432) in the presence of the mutation created a Dde I site. The restriction digests were electrophoresed in 3.5% MetaPhor agarose (FMC Bioproducts, Rockland, ME). For polymorphism analysis, 120
alleles from normal unrelated Caucasian females were assessed by mismatch PCR and digestion with Dde I.
Molecular analysis of the HFE gene. The C282Y and H63D mutations of HFE gene were studied as previously described 5 using HotSTarTaq™ DNA polymerase (Qiagen, Valencia, CA).
The C282Y mutation created an additional Rsa I site while H63D mutation resulted in the deletion of a Sau3A I site. The restriction digests were electrophoresed in 2.5% Ultrapure agarose (Life Technologies).
Promoter-Reporter Gene Expression Construct with the ALAS2 -206G
Mutation. In order to study the effect of the promoter point mutation, constructs were generated using the promoterless pGL3 Basic luciferase reporter vector (Promega, Madison, WI). DNA from a normal individual and the proband's son were used as templates to obtain the normal and the mutant promoter sequences respectively. A GC clamp and a Hind III site were added to the sense primer, while a GC clamp, an Nco I site and the pGL3-Basic sequence from the Nco I site to the Hind III site were added to the antisense primer #769 ( Table 1 were CTGCCAGGGTGCGAGATT and TTGGCTGCTCCACTGTTACG, for FECH they were TTGTTCTCTAAGGCCCTGGC and GCGGACAGCTCAGGGTCA and for GAPDH, they were TCATGGGTGTGAACCATGAGA and GCTTAAGCAGTTGGTGGTGCA.
cDNA was synthesized from 500 ng to 1 µg of total RNA in 100 µl using random hexamers and TaqMan
Reverse Transcription Reagents (Applied Biosystems). Quantitative PCR was performed using 5 µl of cDNA with 400 nM of both sense and antisense primers (Invitrogen, Groningen, the Netherlands) in a final volume of 25 µl using the Sybr Green PCR core reagents in an ABI PRISM 7000 Sequence Detection System instrument (Applied Biosystems). Fluorescence was generated by laser excitation of Sybr Green bound to double-stranded DNA. Single transition dissociation curves for all three amplicons indicated the absence of non-specific side reactions and primer dimer artifacts. PCR conditions were: 2 min (50°C), 10 min (95°C), and 40 cycles of 15 s (95°C) and 1 min (60°C). Measurements were carried out in triplicate for each sample.
GAPDH cDNA amplifications were used to control for variability in the initial quantities of cDNA To evaluate PCR efficiency for each set of primers, serial dilutions of reverse transcribed K562 RNA (1/10 ; 1/100 ; 1/1000) were amplified, and the slopes of plots of C T (test sample cycle threshold (C T ) minus control sample C T ) versus log cDNA input were found to be 0.1, indicating that amplification efficiency was similar and that relative quantitation of ALAS2, FECH and GAPDH was valid. The ALAS2-to-GAPDH and the FECH-to-GAPDH ratios in each sample were calculated using the formula 2 -C T as defined in Applied Biosystems User Bulletin #2: ABI PRISM 7700 Sequence Detection System.
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From Hence, the identity of the terminal nucleotides of the extension products could be read directly from the antisense sequence of the genomic ladder. Major and minor extension products were observed corresponding to 5' UTRs of 52 and 51 nt, respectively (Figure 3) . These results establish the cytosine 52 nt upstream from the translation initiation site as the transcription start site in K562 mRNA. Although the previous study differed from these results in that signals of equal intensity were observed corresponding to 5' UTRs of 53 and 52 in fetal liver mRNA 19 , there too, the same nucleotide was designated as the transcription start site.
RESULTS

Confirmation of the Transcription Initiation
Characterization of Genomic ALAS2 and Identification of a Point Mutation in the ALAS2
Promoter. Sequence analysis of a genomic ALAS2 clone ( 5X-E0) demonstrated that 899 bases 5' of the transcription start site and 109 bases 3' were identical to nucleotides 17289 to 18297 of GenBank Accession number Z83821. The analysis of the 11 exons, the intron-exon junctions This analysis showed that the proband was heterozygous and her affected son was hemizygous for the mutation while the other unaffected family members were normal ( Figure 6A ). This mutation was not found in any of 120 alleles in unrelated Caucasian females, indicating that this mutation was not a polymorphism (data not shown). The levels of ALAS2 and FECH mRNA relative to endogeneous control GAPDH mRNA were determined by real-time quantitative PCR as described in Methods. ALAS2 mRNA from erythroblasts obtained from the proband's peripheral blood BFU-E which had been differentiated in culture for 12 days was reduced, on average, 87±8% (n=3) from that in cells from two normal individuals. Of interest, FECH mRNA in erythroblasts derived from the proband was reduced 61±28% (n=3) from that in the cells from two normal individuals.
Hemochromatosis (HFE) Gene Mutation
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Motif Analysis of the ALAS2 Proximal Promoter Region. The sequence of the region including the promoter point mutation was analyzed for putative transcription factor binding motifs using the MatInspector program version 5 and the Transfac version 5 database based on perfect matches to the core sequences and optimized overall homology. Alignments of putative transcription factor binding sites with the sequence surrounding the -206 mutation (core similarity=0.75) were identified for three factors including Cdx2, the mammalian caudal-related intestinal transcription factor; MEF2, the myocyte enhancer factor; and a half-site for RORE, a hormone response element ( Figure 5B ). Additional putative and known sites in the sequence are noted which may play a role in the regulation of ALAS2 transcription, possibly in relationship with the -206 site.
DISCUSSION
It is not common for point mutations in the promoter region to cause human disease. As of February, 2002, the statistical tables of the Human Gene Mutation Database indicated they accounted for 246 (0.8%) of 30,641 known mutations. 20 Presumably, because multiple factors support the optimal transcriptional complex, a defect in a single transcription factor's binding may not substantially affect the enzymatic activity of the gene product. 21 On the other hand, increasing attention is being focused on regulatory mutations that cause disease. For example, point mutations in five different sites in or adjacent to the EKLF binding motif, CACCC, and in all positions of the TATA motif have been found in patients with -thalassemia. 22 
Mutations in
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From the erythroid-specific GATA1 binding motif, WGATAR, in gene promoters have been shown to cause -thalassemia 23 and congenital erythropoietic porphyria. 24 In this report, the first regulatory mutation in the ALAS2 gene to cause XLSA was identified.
Position -206 in the proximal promoter region of a sideroblastic anemia proband contained a C to G transversion that resulted in moderately late onset of a classical XLSA clinical phenotype in the proband. The proband and her son were the only individuals in this family to have the -206 mutation and to display clinical phenotypes consistent with a defect in heme biosynthesis.
To characterize the mutation's effect with respect to cellular regulation, pGL3 reporter constructs were made containing -293 to +28 of ALAS2 genomic sequence with and without the G to C transversion. Transfection of these constructs in butyrate-induced erythroid K562 cells resulted in a strong (94%) decrease of the activity of the mutated proximal promoter with respect to the wild-type construct. In contrast, this mutation did not lower the luciferase expression in the 293T embryonic kidney cells, indicating that the un-mutated site bound (or failed to bind) an erythroid-specific factor. Confirming the functional relevance of the mutation, real-time quantitative PCR demonstrated that the proband's ALAS2 mRNA level in peripheral erythroblasts was reduced 87% relative to two normal control patients.
Thus, the coincidence of the disease phenotype with the presence of the -206 mutation, the lack of detection of any other mutations in the ALAS2 gene, the absence of this mutation in 120 normal alleles, the functional deficit of promoter activity caused by this mutation in luciferase reporter assays, and the 87% reduction in erythroblast ALAS2 mRNA levels all support the -206C G mutation as the cause of XLSA in this family.
Whereas red cells from female heterozygotes with pyridoxine-responsive XLSA can frequently be separated into two distinct populations of red cells of different size and/or cell density (i.e. intracellular hemoglobin concentration), the red cell size and hemoglobin density histograms for both the proband and her son showed similar broad distributions (Figure 1 ). This is consistent with a nearly complete Lyonization of the proband's marrow erythrocytes to the mutant genotype, the finding of an 87% reduction in ALAS2 mRNA and the clinical expression of the XLSA phenotype.
The modest elevation of free erythrocyte protoporphyrin observed in both the proband and her affected son may be due to the observed 61% reduction in FECH mRNA in peripheral erythroblasts cultivated from the proband. The cause of this reduction is unexplained. It is interesting that total protoporphyrin is also somewhat elevated in the homozygous porphyrias 25 where, as in this case of promoter down-regulated ALAS2, heme pathway intermediates would be expected to be in low concentration. Nonetheless, most studies have found that free erythrocyte protoporphyrin is low in pyridoxine-responsive anemias (e.g. Horrigan and Harris 26 ).
The promoter mutation described in this report altered a region of the human ALAS2 gene in which transcription factor binding sites had not previously been identified. Analysis of the mutation site and nearby sequences using motif search programs such as MatInspector Professional and SIGSCAN identified three candidate transcription factor motifs including Cdx2, MEF2, and RORE (Fig 5B) .
Cdx2 is intestine-specific and a member of the caudal-related homeobox gene family. It participates in the development and differentiation of the intestinal epithelium. [27] [28] [29] With the exception of -206C, the surrounding bases were a perfect match to the matrix consensus ( Figure   5B1 ). Although there are no reports showing erythroid expression of Cdx2, one could speculate that some related protein plays a permissive role in ALAS2 expression.
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The RORE binding protein (Fig 5B2) is a member of a subgroup of the nuclear hormone receptor superfamily for which no ligands have been identified. It can bind to RORE half-sites as a monomer due to the increased specificity of adjacent AT-rich sequences. 30, 31 Adjacent
ROREs similar to those shown in Figure 5B have been shown to serve as binding sites for retinoic acid receptor and retinoid X receptor heterodimers. 32 The expression of nuclear orphan receptor TR4 in hematopoietic cells 33 suggests that some nuclear hormone receptor may be important for ALAS2 transcription.
Members of the MEF2 family were originally shown to regulate the transcriptional activity of most muscle-specific genes in myogenesis. 34 Subsequently, MEF2 was found to play roles in proliferation and apoptosis in additional cell types. 35 The -206G mutation created a nearly perfect match to the MEF2 consensus, (Fig. 5B) , suggesting that an erythroid analogue of MEF2 might be a negative regulatory factor.
It had previously been demonstrated that the region between -124 and -293 bp of the human ALAS2 promoter increased reporter gene expression three-fold in MEL cells and 1.5 fold in K562 cells. 36 Thus, some as yet unidentified transcription factor could be binding to a response element at the -206C site and activating ALAS2. Further studies of the promoter mutation region will require specific binding assays such as electrophoretic shift and footprinting in erythroid cells, to uncover the mechanism by which this mutation disrupts the transcription of ALAS2 gene, perhaps revealing important new functions of the ALAS2 promoter and potentially those of other erythroid-specific genes. 
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